FDA Approves Lilly’s Foundayo Oral GLP-1 Pill for Weight Management

Overview

The FDA has approved orforglipron (Foundayo), a once-daily oral GLP-1 receptor agonist, for chronic weight management in adults with obesity or overweight with related medical conditions. Phase 3 ATTAIN trials demonstrated significant weight loss and improvements in cardiometabolic risk markers with orforglipron compared to placebo.

Background

Obesity and overweight are major risk factors for multiple chronic diseases, necessitating effective long-term weight management strategies. GLP-1 receptor agonists have emerged as effective agents for weight reduction but are often injectable. Orforglipron is a novel, nonpeptide, small-molecule oral GLP-1 receptor agonist designed for once-daily administration without food or water restrictions. The ATTAIN phase 3 program evaluated its efficacy and safety in adults with obesity or overweight, with and without type 2 diabetes.

Data Highlights

Key Findings

• Orforglipron achieved a mean weight loss of up to 27.3 pounds (12.4%) versus 2.2 pounds (0.9%) with placebo in adherent patients over 72 weeks.
• Across all participants, mean weight loss was 25 pounds (11.1%) with orforglipron compared to 5.3 pounds (2.1%) with placebo.
• Treatment improved cardiometabolic risk factors including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.
• Orforglipron is administered orally once daily without food or water intake restrictions.
• Safety warnings include potential thyroid tumors; contraindicated in patients with medullary thyroid carcinoma history or multiple endocrine neoplasia syndrome type 2.
• Common adverse events were gastrointestinal, including nausea, diarrhea, constipation, and vomiting.

Clinical Implications

Orforglipron offers a convenient oral alternative to injectable GLP-1 receptor agonists for chronic weight management in adults with obesity or overweight and related conditions. Clinicians should monitor for thyroid-related risks and counsel patients regarding common gastrointestinal side effects. The drug’s availability through LillyDirect and affordability programs may improve patient access.

Conclusion

The FDA approval of orforglipron provides an effective oral GLP-1 receptor agonist option for sustained weight reduction and cardiometabolic risk improvement in adults with obesity or overweight. Its safety profile and ease of administration support its integration into clinical practice for weight management.

References

1. Eli Lilly and Company 2024 -- FDA Approves Lilly’s Foundayo Oral GLP-1 Pill